New combined treatments, surgery and high-dose-rate interventional radiotherapy (brachytherapy), in advanced ocular surface and eyelid cancers

IF 5 2区医学 Q2 Medicine

Translational Oncology Pub Date : 2024-11-05 DOI:10.1016/j.tranon.2024.102160

Bruno Fionda , Monica Maria Pagliara , Maria Grazia Sammarco , Francesco Pastore , Federico Giannuzzi , Giovanni Cuffaro , Flavia Quaranta Leoni , Luca Tagliaferri , Gustavo Savino

{"title":"New combined treatments, surgery and high-dose-rate interventional radiotherapy (brachytherapy), in advanced ocular surface and eyelid cancers","authors":"Bruno Fionda , Monica Maria Pagliara , Maria Grazia Sammarco , Francesco Pastore , Federico Giannuzzi , Giovanni Cuffaro , Flavia Quaranta Leoni , Luca Tagliaferri , Gustavo Savino","doi":"10.1016/j.tranon.2024.102160","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the clinicopathological characteristics and the effectiveness of post-operative high-dose-rate (HDR) interventional radiotherapy (IRT - brachytherapy) in managing advanced ocular surface squamous neoplasia (OSSN) and eyelid tumors.</div></div><div><h3>Methods</h3><div>Nineteen patients with advanced malignancies affecting the ocular surface (stage ≥ T2) and eyelids (staging ≥ T3) were enrolled. Post-operative HDR-IRT treatment followed surgery after multidisciplinary discussion. In our series a total dose of 49 Gy was administered in 14 fractions of 3.5 Gy each, 2 doses per day. Local disease control is the study's main outcome. Death rate, total survival, disease-free survival, and toxicity are secondary outcomes.</div></div><div><h3>Results</h3><div>Local recurrence was observed in 4 cases, 2 were conjunctival melanomas and 2 were conjunctival squamous cell carcinoma. The median OS was 56.3 months. The 12, 24 and 36 months survival rate was respectively 100.00% (IQR: 100.00% - 100.00%), 100.00% (IQR: 100.00% - 100.00%), 100.00% (IQR: 100.00% - 100.00%) respectively . The median DFS was 56.3 months. The 12, 24 and 36 months disease survival rate was respectively 85.71% (IQR: 69.21% - 100.00%), 68.57% (IQR: 42.11% - 100.00%), 68.57% (IQR: 42.11% - 100.00%) respectively. In eyelid tumors, madarosis and eyelid abnormalities are the main side effects, while in OSSNs, dry eye symptoms are frequently reported.</div></div><div><h3>Conclusion</h3><div>Postoperative HDR-IRT has been effective in advanced eyelid cancers control. More challenging appears instead an effective treatment of advanced OSSNs, particularly conjunctival melanomas. Multicenter studies are needed to get a larger patient sample and to evaluate different radiotherapy dosages by different histologic and T types of tumors.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"51 ","pages":"Article 102160"},"PeriodicalIF":5.0000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523324002857","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

To evaluate the clinicopathological characteristics and the effectiveness of post-operative high-dose-rate (HDR) interventional radiotherapy (IRT - brachytherapy) in managing advanced ocular surface squamous neoplasia (OSSN) and eyelid tumors.

Methods

Nineteen patients with advanced malignancies affecting the ocular surface (stage ≥ T2) and eyelids (staging ≥ T3) were enrolled. Post-operative HDR-IRT treatment followed surgery after multidisciplinary discussion. In our series a total dose of 49 Gy was administered in 14 fractions of 3.5 Gy each, 2 doses per day. Local disease control is the study's main outcome. Death rate, total survival, disease-free survival, and toxicity are secondary outcomes.

Results

Local recurrence was observed in 4 cases, 2 were conjunctival melanomas and 2 were conjunctival squamous cell carcinoma. The median OS was 56.3 months. The 12, 24 and 36 months survival rate was respectively 100.00% (IQR: 100.00% - 100.00%), 100.00% (IQR: 100.00% - 100.00%), 100.00% (IQR: 100.00% - 100.00%) respectively . The median DFS was 56.3 months. The 12, 24 and 36 months disease survival rate was respectively 85.71% (IQR: 69.21% - 100.00%), 68.57% (IQR: 42.11% - 100.00%), 68.57% (IQR: 42.11% - 100.00%) respectively. In eyelid tumors, madarosis and eyelid abnormalities are the main side effects, while in OSSNs, dry eye symptoms are frequently reported.

Conclusion

Postoperative HDR-IRT has been effective in advanced eyelid cancers control. More challenging appears instead an effective treatment of advanced OSSNs, particularly conjunctival melanomas. Multicenter studies are needed to get a larger patient sample and to evaluate different radiotherapy dosages by different histologic and T types of tumors.

查看原文本刊更多论文

针对晚期眼表癌和眼睑癌的新型综合疗法--手术和高剂量率介入放射治疗（近距离放疗）。

目的：评估晚期眼表鳞状肿瘤（OSSN）和眼睑肿瘤的临床病理特征以及术后高剂量率（HDR）介入放射治疗（IRT-近距离放射治疗）的疗效：方法：19 名患有晚期眼表恶性肿瘤（分期≥ T2）和眼睑恶性肿瘤（分期≥ T3）的患者入选。经多学科讨论后，患者在手术后接受 HDR-IRT 治疗。在我们的系列研究中，总剂量为 49 Gy，分 14 次进行，每次 3.5 Gy，每天 2 次。局部疾病控制是研究的主要结果。死亡率、总生存率、无病生存率和毒性是次要结果：结果：4例观察到局部复发，其中2例为结膜黑色素瘤，2例为结膜鳞状细胞癌。中位生存期为 56.3 个月。12、24和36个月的生存率分别为100.00%（IQR：100.00% - 100.00%）、100.00%（IQR：100.00% - 100.00%）、100.00%（IQR：100.00% - 100.00%）。中位生存期为 56.3 个月。12、24和36个月的疾病生存率分别为85.71%（IQR：69.21% - 100.00%）、68.57%（IQR：42.11% - 100.00%）、68.57%（IQR：42.11% - 100.00%）。眼睑肿瘤的主要副作用是眩晕和眼睑异常，OSSN的主要副作用是干眼症状：结论：术后 HDR-IRT 对晚期眼睑癌的控制有效。结论：术后 HDR-IRT 能有效控制晚期眼睑癌，但要有效治疗晚期 OSSN，尤其是结膜黑色素瘤，似乎更具挑战性。需要进行多中心研究，以获得更多的患者样本，并评估不同组织学和T型肿瘤的不同放疗剂量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.